• Adrenal function
Serving Size: 3 Capsules... %DV
Pantethine (Vitamin B5)... 900 mg... 9000%
What Is It?
Supplementing with regular B5 or pantothenic acid will not necessarily increase the body's levels of pantethine since this conversion process is tightly regulated. In 1996, AOR released the first Canadian standalone vitamin B5 in the form of Pantethine. Unlike many others since, AOR's Pantethine provides a pure, effective form of this important nutrient at a research-supported dose.
What Does It Do?
Primary Uses: Low pantethine levels can result in blood lipid imbalances. Pantethine's role in the body is related to coenzyme A, which is involved in hundreds of metabolic processes including energy production and fatty acid synthesis. Pantethine regulates the production of total cholesterol, triglycerides, LDL, and HDL, supporting healthy cholesterol levels, a role that is not shared by pantothenic acid.
Secondary Uses: Coenzyme A is required for the synthesis of stress hormones in the adrenal glands. An inadequate supply of pantethine may therefore result in adrenal insufficiency, which compromises immunity, energy, metabolism and overall well-being. Coenzyme A is also essential for phase II liver detoxification, and pantethine may protect against fatty liver degeneration and other types of liver damage better than regular B5.
Who Should Take It?
Pantethine is an excellent natural support for those with abnormal blood lipids, for those dealing with constant stress and for those with liver disorders.
Take 3 capsules daily with food, or as directed by a qualified health care practitioner.
Bertolini S, Donati C, Elicio N, et al. “
Lipoprotein changes induced by pantethine in hyperlipoproteinemic patients: adults and children.”
Int J Clin Pharmacol Ther Toxicol. 1986 Nov; 24(11): 630-7.
Donati C, Bertieri RS, Barbi G. “
Pantethine, diabetes mellitus and atherosclerosis. Clinical study of 1045 patients.”
Clin Ter. 1989 Mar 31; 128(6): 411-22.
Osono Y, Hirose N, Nakajima K, Hata Y. “
The effects of pantethine on fatty liver and fat distribution.”
J Atheroscler Thromb. 2000 7(1) 55-8.
Tarasov IuA, Sheibak VM, Moiseenok AG. “
Adrenal cortex functional activity in pantothenate deficiency and the dministration of the vitamin or its derivatives.”
Vopr Pitan. 1985 Jul-Aug;(4) 51-4.
Wittwer CT, Graves CP, Peterson MA, Jorgensen E, Wilson DE, Thoene JG, Wyse BW, Windham CT, Hansen RG. “
Pantethine lipomodulation: evidence for cysteamine mediation in vitro and in vivo.”
Atherosclerosis. 1987 Nov; 68(1-2): 41-9.
Disclaimer: This content is subject to change. The information is intended to inform and educate; it does not replace the medical evaluation, advice, diagnosis or treatment by a healthcare professional. www.nhpassist.com © 2014 NDAssist Inc. and/or its affiliates. All rights reserved.